 A PILOT STUDY OF SEQUENTIAL ONCOS-102, AN ENGINEERED ONCOLYTIC ADENOVIRUS EXPRESSING GMCSF, AND PEMBROLIZUMAB IN PATIENTS WITH ADVANCED OR UNRESECTABLE MELANOMA PROGRESSING AFTER PROGRAMMED CELL DEATH PROTEIN 1 PD1 BLOCKADE: 